Eli Lilly and Company (NYSE:LLY) Holdings Boosted by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 516,804 shares of the company’s stock after acquiring an additional 8,309 shares during the period. Eli Lilly and Company accounts for 0.5% of Russell Investments Group Ltd.’s investment portfolio, making the stock its 19th biggest holding. Russell Investments Group Ltd. owned 0.05% of Eli Lilly and Company worth $301,107,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of LLY. Private Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 31.9% in the 4th quarter. Private Wealth Partners LLC now owns 4,730 shares of the company’s stock valued at $2,757,000 after purchasing an additional 1,145 shares during the last quarter. Valmark Advisers Inc. lifted its stake in shares of Eli Lilly and Company by 1.5% in the 4th quarter. Valmark Advisers Inc. now owns 4,543 shares of the company’s stock valued at $2,648,000 after purchasing an additional 69 shares during the last quarter. Gilliland Jeter Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $673,000. Terril Brothers Inc. lifted its stake in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares during the last quarter. Finally, Headlands Technologies LLC lifted its stake in shares of Eli Lilly and Company by 82.7% in the 4th quarter. Headlands Technologies LLC now owns 3,710 shares of the company’s stock valued at $2,163,000 after purchasing an additional 1,679 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $8.64 during mid-day trading on Friday, hitting $733.51. The company’s stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. Eli Lilly and Company has a fifty-two week low of $380.77 and a fifty-two week high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.47, a P/E/G ratio of 1.58 and a beta of 0.34. The stock has a fifty day moving average of $761.79 and a 200-day moving average of $666.06.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $2.09 earnings per share. As a group, equities analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Truist Financial restated a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a report on Monday, April 15th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a report on Wednesday, February 21st. Finally, Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.